Northwest Biotherapeutics, Inc. (NWBO)

Market Cap	561.78M
Revenue (ttm)	1.93M
Net Income (ttm)	-62.23M
Shares Out	1.19B
EPS (ttm)	-0.06
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,867,962
Open	0.499
Previous Close	0.480
Day's Range	0.463 - 0.500
52-Week Range	0.400 - 1.090
Beta	-0.70
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 28, 2023

About NWBO

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors....

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 25
• Stock Exchange: OTCMKTS
• Ticker Symbol: NWBO

Financial Performance

In 2023, NWBO's revenue was $1.93 million, an increase of 14.80% compared to the previous year's $1.68 million. Losses were -$62.60 million, -54.26% less than in 2022.